{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:11:42Z","timestamp":1793927502630,"version":"4.8.0"},"reference-count":43,"publisher":"BMJ","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canadian College of Medical Geneticists"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Purpose and scope<\/jats:title>\n                  <jats:p>The aim of this position statement is to provide recommendations aimed at Canadian reproductive care clinicians and genetics professionals regarding the use of reproductive carrier screening for autosomal recessive and X-linked recessive conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods of statement development<\/jats:title>\n                  <jats:p>A multidisciplinary expert group was assembled to review the existing literature on reproductive carrier screening for autosomal recessive and X-linked recessive conditions and make recommendations relevant to the Canadian context. The statement was circulated for comment to the membership of the Canadian College of Medical Geneticists (CCMG) and Canadian Association of Genetic Counsellors (CAGC), and multiple family physician reviewers. Feedback from these groups was incorporated, and the final position statement was approved by the CCMG Board of Directors on 5 December 2024 and the CAGC Board of Directors on 14 April 2025.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and conclusions<\/jats:title>\n                  <jats:p>Routinely offered pan-ethnic reproductive carrier screening via a provincial or territorial programme is recommended for a limited panel of relatively common and severe childhood onset genetic conditions, based on Canadian experience with ethnicity-based testing: cystic fibrosis, fragile X syndrome, spinal muscular atrophy, haemoglobinopathies and founder mutations for Tay-Sachs disease, Canavan disease and familial dysautonomia. Provincial\/territorial programmes must be developed to provide oversight, ensure appropriate resourcing and manage education and roll-out. Maintaining regional ethnicity-based screening programmes is also recommended, where relevant. Publicly funded population-level expanded carrier screening is not recommended at this time.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmg-2025-110871","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T01:30:26Z","timestamp":1756085426000},"page":"jmg-2025-110871","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Reproductive carrier screening for genetic disorders: position statement of the Canadian College of Medical Geneticists"],"prefix":"10.1136","author":[{"given":"Ritu B","family":"Aul","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2222-7800","authenticated-orcid":false,"given":"Karen Elizabeth","family":"Canales","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-2991","authenticated-orcid":false,"given":"Isabelle","family":"De Bie","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Laberge","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Social and Preventative Medicine, School of Public Health, Universite de Montreal, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Langlois","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-3516","authenticated-orcid":false,"given":"Tanya N","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Genome Diagnostics, Department of Pathology & Laboratory Medicine, BC Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-2028","authenticated-orcid":false,"given":"Sakina","family":"Walji","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-5112","authenticated-orcid":false,"given":"Andrea C","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2709-5049","authenticated-orcid":false,"given":"Joanna","family":"Lazier","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Children\u2019s Hospital of Eastern Ontario, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"key":"2025082418300963000_jmg-2025-110871v1.1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/jcm3031033","article-title":"Carrier Screening: Past, Present, and Future","volume":"3","author":"Bajaj","year":"2014","journal-title":"JCM"},{"key":"2025082418300963000_jmg-2025-110871v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01203-z"},{"key":"2025082418300963000_jmg-2025-110871v1.3","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s10815-022-02653-3","article-title":"Considerations on the use of carrier screening testing in human reproduction: comparison between recommendations from the Italian Society of Human Genetics and other international societies","volume":"39","author":"Capalbo","year":"2022","journal-title":"J Assist Reprod Genet"},{"key":"2025082418300963000_jmg-2025-110871v1.4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pd.5611","article-title":"International perspectives on the implementation of reproductive carrier screening","volume":"40","author":"Delatycki","year":"2020","journal-title":"Prenat Diagn"},{"key":"2025082418300963000_jmg-2025-110871v1.5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jogc.2016.06.008","article-title":"Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing","volume":"38","author":"Wilson","year":"2016","journal-title":"J Obstet Gynaecol Can"},{"key":"2025082418300963000_jmg-2025-110871v1.6","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31821922c2"},{"key":"2025082418300963000_jmg-2025-110871v1.7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jgc4.1676","article-title":"Expanded carrier screening for reproductive risk assessment: An evidence-based practice guideline from the National Society of Genetic Counselors","volume":"32","author":"Sagaser","year":"2023","journal-title":"J Genet Couns"},{"key":"2025082418300963000_jmg-2025-110871v1.8","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/AOG.0000000000001951","article-title":"Committee Opinion no.690: Carrier Screening in the Age of Genomic Medicine","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"2025082418300963000_jmg-2025-110871v1.9","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001952"},{"key":"2025082418300963000_jmg-2025-110871v1.10","unstructured":"The Royal Australian and New Zealand College of Obstetricians and Gynaecologists . Genetic carrier screening. Available: https:\/\/ranzcog.edu.au\/wp-content\/uploads\/Genetic-Carrier-Screening.pdf"},{"key":"2025082418300963000_jmg-2025-110871v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0869-3"},{"key":"2025082418300963000_jmg-2025-110871v1.12","unstructured":"Beauchamp TL . Principles of Biomedical Ethics. 6th edn. New York: Oxford University Press, 2009."},{"key":"2025082418300963000_jmg-2025-110871v1.13","unstructured":"Tulandi T , Al-Fozan H . Recurrent pregnancy loss: evaluation. Available: https:\/\/www.uptodate.com\/contents\/recurrent-pregnancy-loss-evaluation [Accessed 5 Apr 2025]."},{"key":"2025082418300963000_jmg-2025-110871v1.14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.rbmo.2021.02.014","article-title":"Clinical practice guidelines for recurrent miscarriage in high-income countries: a systematic review","volume":"42","author":"Hennessy","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025082418300963000_jmg-2025-110871v1.15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jogc.2017.07.024","article-title":"Woman\u2019s Pre-Conception Evaluation: Genetic and Fetal Risk Considerations for Counselling and Informed Choice","volume":"40","author":"Wilson","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"key":"2025082418300963000_jmg-2025-110871v1.16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mgg3.204","article-title":"Carrier screening by next-generation sequencing: health benefits and cost effectiveness","volume":"4","author":"Azimi","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"2025082418300963000_jmg-2025-110871v1.17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.gim.2022.02.011","article-title":"Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen","volume":"24","author":"Beauchamp","year":"2022","journal-title":"Genet Med"},{"key":"2025082418300963000_jmg-2025-110871v1.18","unstructured":"Medical Services Advisory Committee . Reproductive carrier screening for fragile x syndrome, spinal muscular atrophy and cystic fibrosis. Medical Services Advisory Committee; 2022. Available: https:\/\/www.msac.gov.au\/applications\/1573 [Accessed 5 Apr 2025]."},{"key":"2025082418300963000_jmg-2025-110871v1.19","unstructured":"Medical Services Advisory Committee . Cystic fibrosis transmembrane regulator (CFTR) testing. 2017. Available: https:\/\/www.msac.gov.au\/sites\/default\/files\/documents\/1216.1-FinalPSD-accessible.pdf"},{"key":"2025082418300963000_jmg-2025-110871v1.20","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"key":"2025082418300963000_jmg-2025-110871v1.21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/pd.6027","article-title":"The cost-effectiveness of genotyping versus sequencing for prenatal cystic fibrosis carrier screening","volume":"41","author":"Avram","year":"2021","journal-title":"Prenat Diagn"},{"key":"2025082418300963000_jmg-2025-110871v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4585"},{"key":"2025082418300963000_jmg-2025-110871v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.02.007"},{"key":"2025082418300963000_jmg-2025-110871v1.24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.gim.2021.09.009","article-title":"A guidelines-consistent carrier screening panel that supports equity across diverse populations","volume":"24","author":"Johansen Taber","year":"2022","journal-title":"Genet Med"},{"key":"2025082418300963000_jmg-2025-110871v1.25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/cge.14148","article-title":"Carrier frequency of autosomal recessive genetic conditions in diverse populations: Lessons learned from the genome aggregation database","volume":"102","author":"Schmitz","year":"2022","journal-title":"Clin Genet"},{"key":"2025082418300963000_jmg-2025-110871v1.26","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.socscimed.2011.09.031","article-title":"\u201cThe Most Important Test You\u2019ll Ever Take\u201d?: attitudes toward confidential carrier matching and open individual testing among modern-religious Jews in Israel","volume":"73","author":"Frumkin","year":"2011","journal-title":"Soc Sci Med"},{"key":"2025082418300963000_jmg-2025-110871v1.27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41431-022-01178-8","article-title":"Societal implications of expanded universal carrier screening: a scoping review","volume":"31","author":"van den Heuvel","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"2025082418300963000_jmg-2025-110871v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0273-4"},{"key":"2025082418300963000_jmg-2025-110871v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.97"},{"key":"2025082418300963000_jmg-2025-110871v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.271"},{"key":"2025082418300963000_jmg-2025-110871v1.31","unstructured":"Genetic Disease Screening program . Cree health. 2025. Available: https:\/\/www.creehealth.org\/services\/ce-cle [Accessed 5 Apr 2025]."},{"key":"2025082418300963000_jmg-2025-110871v1.32","unstructured":"Offres de tests de porteurs pour les maladies h\u00e9r\u00e9ditaires autosomiques r\u00e9cessives disponibles au qu\u00e9bec. gouvernement du qu\u00e9bec. Available: https:\/\/www.quebec.ca\/sante\/problemes-de-sante\/a-z\/maladies-hereditaires-recessives\/tests-porteur-maladies-hereditaires-autosomiques-recessives\/offres-tests-porteurs-maladies-hereditaires-autosomiques-recessives-disponibles-quebec [Accessed 5 Apr 2025]."},{"key":"2025082418300963000_jmg-2025-110871v1.33","doi-asserted-by":"crossref","first-page":"104075","DOI":"10.1016\/j.ejmg.2020.104075","article-title":"Which types of conditions should be included in reproductive genetic carrier screening? Views of parents of children with a genetic condition","volume":"63","author":"Thomas","year":"2020","journal-title":"Eur J Med Genet"},{"key":"2025082418300963000_jmg-2025-110871v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0466-5"},{"key":"2025082418300963000_jmg-2025-110871v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0472-7"},{"key":"2025082418300963000_jmg-2025-110871v1.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314768"},{"key":"2025082418300963000_jmg-2025-110871v1.37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5694\/mja2.50789","article-title":"Ethical issues in reproductive genetic carrier screening","volume":"214","author":"Dive","year":"2021","journal-title":"Med J Aust"},{"key":"2025082418300963000_jmg-2025-110871v1.38","unstructured":"Canadian College of Medical Geneticists. Medical Genetics . Choosing wisely canada. 2024. Available: https:\/\/choosingwiselycanada.org\/recommendation\/medical-genetics\/ [Accessed 5 Apr 2025]."},{"key":"2025082418300963000_jmg-2025-110871v1.39","unstructured":"Canada S . Table 98-10-0303-01 citizenship by visible minority and immigrant status and period of immigration: canada, provinces and territories and federal electoral districts (2013 representation order). 2022. Available: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=9810030301"},{"key":"2025082418300963000_jmg-2025-110871v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2012.114"},{"key":"2025082418300963000_jmg-2025-110871v1.41","first-page":"1","article-title":"Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment","volume":"23","year":"2023","journal-title":"Ont Health Technol Assess Ser"},{"key":"2025082418300963000_jmg-2025-110871v1.42","doi-asserted-by":"crossref","first-page":"100813","DOI":"10.1016\/j.gim.2023.100813","article-title":"Economic evaluation of population-based, expanded reproductive carrier screening for genetic diseases in Australia","volume":"25","author":"Schofield","year":"2023","journal-title":"Genet Med"},{"key":"2025082418300963000_jmg-2025-110871v1.43","unstructured":"The Ashkenazi Jewish screening program . McGill university health centre. Available: https:\/\/muhc.ca\/med-genetics-ajprogram [Accessed 5 Apr 2025]."}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2025-110871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T01:30:32Z","timestamp":1756085432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2025-110871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":43,"alternative-id":["10.1136\/jmg-2025-110871"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2025-110871","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,24]]}}}